Investigation of Variants In SARS-CoV-2 Infections after Three Doses of COVID-19 Vaccine

Authors : Burcu GÜRER GİRAY, Gökçe GÜVEN AÇIK

Pages : 820-823

Doi:10.16899/jcm.1343574

View : 51 | Download : 35

Publication Date : 2023-09-30

Article Type : Research Paper

Abstract :Abstract Objective: Our study focused on retrospectively assessing variant of concern, specified by the World Health Organization insert ignore into journalissuearticles values(WHO);, with one-step reverse transcription and real-time polymerase chain reaction insert ignore into journalissuearticles values(RT-PCR); test in SARS-CoV-2 positive patients after three doses of attenuated COVID-19 vaccine. Methods: 8.520 samples transported with viral nucleic acid buffer insert ignore into journalissuearticles values(vNAT); tubes between June 2021 and January 31, 2022, were tested and included in the study. All the patients whose samples were included in our research had 3 doses of CoronaVac insert ignore into journalissuearticles values(Sinovac Life Science Co, Ltd, Beijing, China);. Gender distribution was 4686 insert ignore into journalissuearticles values(55%); female and 3834 insert ignore into journalissuearticles values( 45%); males. Variant specific genome regions only found in B.1.351, P.1 and B.1.1.7 as well as ORF1ab and N gene regions are investigated by the Bio-Speedy® Emerging Plus kit insert ignore into journalissuearticles values(Bioeksen AR-GE Technologies, Turkey); used to identify the variants in the study. Results: All 8.520 samples were SARS-CoV-2 RT-PCR positive. Our study detected alpha and delta variants in 1460 insert ignore into journalissuearticles values(17.14%); and 3570 insert ignore into journalissuearticles values(41.9%); patients respectively. 2570 insert ignore into journalissuearticles values(30.16%); patients did not have any variants according to test results. It was observed that the spread of beta, gamma and other suspicious variants remained at relatively low rates. Conclusion: The delta variant became dominant from July until to the end of the year. Declining delta variant rates and increasing cases of suspected variants towards the beginning of December 2021 suggest the omicron variant. Therefore, molecular surveillance studies that are planned to take epidemiological data into consideration and to examine the prevalence and gene-based analysis of local and worldwide variants are required.
Keywords : Sars Cov 2, B 1 1 7 VARYANTI, B 1 351 VARYANTI

ORIGINAL ARTICLE URL